Scandion Oncology

Overcoming cancer drug resistance

Scandion Oncology (Scandion) today announces its interim report for Q2 2023. The following is taken from the report. Francois Martelet, CEO: “A successful patent application puts us on the brink of having almost 20 years of exclusivity on our lead compound SCO-101” Key Figures & Highlights TDKK Q2 2023 Q1-Q2 2023 Q2 2022 Q1-Q2 2022 FY 2022 Operating loss -11,318 -23,292 -24,840 -41,152 -80,166 Net finance income/cost 66 131 -37 -288 -2,034 Loss before tax -11,253 -23,160 -24,877 -41,440 -82,200 Net loss -8,774 -18,062 -23,021 -35,940 -76,700 Total assets 60,186 60,186 87,728 87,728 89,401 Cash Position 45,709 45,709 72,667 72,667 77,605 Total equity 52,265 52,265 67,769 67,769 70,327 Equity ratio 87% 87% 77% 77% 79% Earnings per share (EPS) -0.22 -0.57 -0.72 -1.12 -1.88 Shares outstanding, ending 40,706,972 40,706,972 32,135,544 32,135,544 40,706,972             Highlights during Q2 2023 On April 26 Scandion announced results of the Annual General Meeting. Highlights after the end of the period On July 18, The European Patent Office announced intention to grant of Composition-of-Matter patent for Scandion Oncology’s lead compound SCO-101. If granted, the patent will cover the commercial solid form of SCO-101 until at least 2042. On August 17, Data from PANTAX trial to be presented at ESMO Congress 2023. The interim report Q2 2023 is available on the Company's website: www.scandiononcology.com. Audiocast today, August 23 at 10:00 am CET Today at 10:00, Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update. At the end of the presentation there will be a Q&A session. Access to the event can be obtained as follows: LIVE access on Wednesday August 23, 2023, at 10:00 CET: https://financialhearings.com/event/46155 REPLAY accessWebcast replay will be available at www.scandiononcology.com in the Investors section and at www.financialhearings.com For further information please contact:Johnny Stilou, CFOPhone: +45 2960 3532E-mail: jos@scandiononcology.com The information was provided by the contact person above for publication on August 23, 2023, at 08.30 CET. Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer. […]

Safety data from the PANTAX trial, studying SCO-101 in pancreatic cancer, has been accepted for poster presentation. Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, will have clinical safety data for its lead compound SCO-101 presented at the European Society for Medical Oncology (ESMO) Congress 2023 taking place in Madrid on October 20-24, 2023. This will be a good opportunity for Scandion to make the safety data available to a large number of international physicians and other stakeholders. Safety data from the PANTAX phase 1b trial in patients with pancreatic cancer will be announced at a poster presentation at the congress. This data will provide details to the topline results communicated in March 2023. The primary endpoint of the PANTAX trial was achieved as the maximum tolerated dose of SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer was established at 200 milligrams given for 6 consecutive days every 2 weeks. Scandion expects to perform a full analysis of all safety and efficacy outcomes late in 2023 with the final data to be presented in H1 2024. For further information please contact:Johnny Stilou, CFOPhone: +45 2960 3532E-mail: jos@scandiononcology.com The information was provided by the contact person above for publication on August 17, 2023, at 08.30 CET. Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer. Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant. Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market. AttachmentsScandion Oncology To Present Data From PANTAX […]